|Articles|September 19, 2016
ERT eCOA Solution Assists in Migraine Study
ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study.
Advertisement
ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study. Patients used the solution to record migraine occurrence and rate headache pain severity as well as other symptoms.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Ensuring Digital Trial Platforms Work for Underserved CommunitiesSeptember 10th 2025
eClinical Technology: Misconceptions, Challenges, and OpportunitiesSeptember 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
2
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
